NEW YORK, May 14, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter Magazine has just published exclusive interviews with executives from INNOVIVE Pharmaceuticals (OTCBB:IVPH), DNAPrint(tm) Genomics Inc. (OTCBB:DNAG), and GangaGen Inc. (Private Equity) -- all companies that are poised to take their businesses to the next level.
All three interviews are now available at http://wallstreetreporter.com in streaming audio, MP3, and text format -- all free of charge.
In the oncology space, Steven Kelly, President and CEO of INNOVIVE Pharmaceuticals (OTCBB:IVPH) tells Wall Street Reporter senior analyst Todd Santorelli that a recent $15 million equity financing round will help push his company's four distinct clinical-stage programs forward through the clinic.
Areas covered in especially extensive detail include:
* How the company plans to use the proceeds of a recent $15 million equity round to advance its entire pipeline. "These funds will allow us to proceed with drug development on all four of our clinical-stage compounds," he says. * His lead program's billion-dollar potential as a treatment for chronic myelod leukemia (CML), a market where Novartis Gleevec has already created a $2.5 billion market. "This drug will compete in the CML marketplace, not necessarily head-to-head with Gleevec, but it'll be looking at the Gleevec-refractory patient population." * How the company's follow-up programs for various leukemias and small-cell cancers create revenue opportunities in the $100 million to $500 million range. * Existing and prospective relationships with overseas pharma and academic organizations.
"We have a more robust portfolio of drugs," he says. "We have four distinct shots on goal. All of them are legitimate shots on goal within the next three years."
From the emerging area of pharmacogenomics, Richard Gabriel, CEO of DNAPrint(tm) Genomics Inc. (OTCBB:DNAG), tells Wall Street Reporter senior analyst Todd Santorelli that his company is at the forefront of efforts to create "theranostics," combinations of drugs with genetic diagnostic tools to help clinicians tailor treatment to patients' genetic makeup.
"People are trying to figure out what personalized medicine means," he says. "We believe we've already accomplished that."
In the exclusive interview, Mr. Gabriel covers the following topics in particular detail:
* The company's existing genetic ancestry testing and forensic genomics businesses. * His strategic focus on licensing and technology. "One lead compound is being evaluated by NIDA (the National Institute on Drug Abuse)," he says. "We have two other compounds which we've identified for attention deficit disorder as well as depression." * How the company's technology has already been validated and now commercialization is simply a matter of capital. "Our product is more effective, less toxic, and we will link it with genetic ancestry as well as other diagnostics to avoid patient use problems."
Finally, GangaGen Inc. (Private Equity) is getting close to bringing its novel anti-microbial technology to bear on the problem of drug-resistant infectious disease, says Dr. Rainer Engelhardt, the company's CEO. "In the area of antibiotic-resistant bacterial disease, investors should see us not only as an existing leader, but as a continuing leader," he tells Wall Street Reporter's Todd Santorelli. "We do anticipate being on the market with a phage product as early as next year."
Key areas covered in the exclusive interview include:
* An overview of GangaGen's unique technology, which utilizes the bacteria-eating ability of naturally-occurring microbes to fight the growing clinical problem of acquired antibiotic resistance. "Antibiotic-resistant bacteria and the infectious diseases associated with them generally speak to a global problem," Dr. Engelhardt says. "It can be a very serious healthcare issue." * The company's secure intellectual property position. * An established partnership with Eli Lilly & Co. (NYSE: LLY) animal health subsidiary Elanco to eliminate E. coli contamination in meat products. * Dr. Engelhardt's confidence that the company should bring a program into the clinic within the next year.
"Our short- to mid-term vision is to take our animal health products, the leading products in terms of their development path, into the market," he tells Wall Street Reporter. "We anticipate having a product on the market by next year if all goes well on the regulatory side."
About Wall Street Reporter
Wall Street Reporter (Est. 1843) helps smart investors connect with exciting companies, through our website, magazines, and conferences. We're probably best known for our exclusive interviews with industry-leading CEOs and the world's top investment experts.
Wall Street Reporter produces in-depth, unbiased, unfiltered interviews that deliver a first-hand, straight-from-the-source perspective. This enables our audience to make intelligent and informed investment decisions.
About INNOVIVE Pharmaceuticals
INNOVIVE Pharmaceuticals is a biopharmaceutical company headquartered in midtown Manhattan. Our mission is to acquire, develop, and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. INNOVIVE is grounded in scientific and technical excellence. We are committed to creating value for shareholders, employees, caregivers and patients who use our products.
About DNAPrint(tm) Genomics Inc.
DNAPrint(tm) Genomics Inc. is a cutting-edge company. We are concentrating our efforts in four distinct areas: pharmacogenomics, forensics, genotyping, and consumer products. Our aim is to continue to research and develop novel products and services in each of these market areas and to be a leader in genomic-based technologies.
About GangaGen Inc.
GangaGen is a privately held, Delaware-incorporated biotechnology company focused on the research, development and commercialization of proprietary bacteriophage-based treatments for the control and elimination of bacteria that cause human disease and as a solution to the worldwide problem of antibiotic resistance. The company's subsidiary in India (GangaGen Biotechnologies Pvt. Ltd) focuses on bacteriophage research and the development of phage preparations for direct human applications. The Canadian subsidiary (GangaGen Life Sciences Inc.) focuses on developing phage preparations to eliminate from food animals and their environment bacteria potentially harmful to humans before they can be transmitted to humans. Headquarters for GangaGen Inc. is in San Francisco, California.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.